Results 31 to 40 of about 31,287 (200)

Reversal of myelofibrosis by hydroxyurea [PDF]

European Journal of Haematology, 1990
Abstract: Bone marrow morphology in 39 symptomatic patients with myeloproliferative disorders (polycythaemia vera 15, essential thrombocythaemia 14, idiopathic myelofibrosis 9, myeloproliferative syndrome 1) and elevated platelet counts was studied before and after a median of 18 months of continuous treatment with hydroxyurea.
E, Löfvenberg, A, Wahlin, G, Roos, A, Ost   +3 more
openaire   +2 more sources

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia

Trials, 2020
Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide.
Emily R. Meier, Susan E. Creary, Matthew M. Heeney, Min Dong, Abena O. Appiah-Kubi, Stephen C. Nelson, Omar Niss, Connie Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, Kay L. Saving, John P. Scott, Ravi Talati, Teresa S. Latham, Amanda Pfeiffer, Lisa M. Shook, Alexander A. Vinks, Adam Lane, Patrick T. McGann   +18 more
doaj   +1 more source

Natural History of Chronic Kidney Disease in Sickle Cell Disease. [PDF]

Am J Hematol
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Ataga KI.
europepmc   +2 more sources

Melanonychia secondary to hydroxyurea [PDF]

Internal and Emergency Medicine, 2011
A 69-year-old woman with recently diagnosed, essential thrombocytosis was treated with hydroxyurea (1 g daily) and anagrelide (0.5 mg twice daily) for 4 weeks. Because of well-controlled platelet count, the use of hydroxyurea was suspended. One month later, she presented to our emergency department (ED) with an extraordinarily high platelet count (2 ...
Po-Hua, Su, Chorng-Kuang, How, David Hung-Tsang, Yen, Mu-Shun, Huang   +3 more
openaire   +2 more sources

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi, Dorothée Selimoglu‐Buet, Ivan Sloma, Orianne Wagner‐Ballon, on behalf of the French group CytHem‐LMMC   +4 more
wiley   +1 more source

Mosaic activation of the zebrafish hsp70l heat shock promoter: Implications for interpreting transgenes

Developmental Dynamics, EarlyView.
Abstract Background The promoters and enhancers of heat shock genes, such as the 1.5‐kb promoter of the zebrafish hsp70l gene, are valuable tools for temporal activation of transgenes. It has been widely purported that heat shock treatments result in ubiquitous expression of hsp70l‐driven transgenes.
Jong‐Su Park, Xiangyun Wei
wiley   +1 more source

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

Einstein (São Paulo)
Objective To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.
Emanuel Almeida Moreira de Oliveira, Kenia de Assis Boy, Ana Paula Pinho Santos, Carla da Silva Machado, Cibele Velloso-Rodrigues, Pâmela Souza Almeida Silva Gerheim, Leonardo Meneghin Mendonça   +6 more
doaj   +1 more source

Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males

Haematologica, 2008
Background Recent progress in the treatment of sickle cell disease, in particular the use of hydroxyurea, has considerably modified the prognosis of this disease. Many more patients now reach reproductive age.
Isabelle Berthaut, Geoffroy Guignedoux, Frederique Kirsch-Noir, Vanina de Larouziere, Celia Ravel, Dora Bachir, Frédéric Galactéros, Pierre-Yves Ancel, Jean-Marie Kunstmann, Laurence Levy, Pierre Jouannet, Robert Girot, Jacqueline Mandelbaum   +12 more
doaj   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, EarlyView.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source